Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Advances in Diagnosis and Treatment of Cardiovascular and Metabolic Diseases
share announcement

Advances in Diagnosis and Treatment of Cardiovascular and Metabolic Diseases

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Lipid Metabolism".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 2831

Special Issue Editors

Dr. Suowen Xu

E-Mail Website
Guest Editor
Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230037, China
Interests: atherosclerosis; cardiovascular disease; pharmacology; natural products
Special Issues, Collections and Topics in MDPI journals
Dr. Li Wang

E-Mail Website
Guest Editor
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong 999077, China
Interests: hemodynamic shear stress and the endothelium in the process of atherosclerosis; the role of Hippo pathway in cardiovascular regulation; the endocrine function of endothelium in health and disease; identification of new biomarker(s) for early diagnosis of atherosclerotic vascular disease; identification of new compounds for atherosclerosis prevention and treatment; inter-organ crosstalk and physical exercise
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Yu Huang

E-Mail Website
Guest Editor
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong 999077, China
Interests: vascular biology; endothelium; endothelial dysfunction; atherosclerosis; vascular inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

During the last decade, great strides have been made in our understanding of diagnostics and pharmacotherapy for cardiovascular and metabolic diseases. To name a few, the anti-inflammatory therapies with anti-interleukin 1 beta and colchicine marked the concept of “anti-inflammation therapy in atherosclerosis” becoming reality. Additionally, with the advancement of high-throughput technologies such as single-cell RNA sequencing and high content screening, more potential drugs targeting cardiovascular and metabolic diseases have been identified and experimentally validated. These drug candidates provide a good template for the future development of new drugs against cardiovascular and metabolic diseases. The recent resurgence of interest in connectivity MAP (cMAP) has allowed for the in silico discovery of novel drug candidates from natural sources or the FDA-approved drug library to treat obesity, fatty liver, and cardiovascular diseases. Other technologies such as metabolomics and lipidomics have enabled biomarker discovery and validation. Integrative multiomics are powerful tools for the diagnostics and treatment of cardiovascular and metabolic diseases. This Special Issue is devoted to the use of advanced technologies to diagnose and treat cardiovascular and metabolic diseases. Topics of interest include, but are not limited to, new therapeutic targets in lipid metabolism, inflammation, and metabolic disorders. We welcome the submission of preclinical, clinical, and translational studies related to theranostics of cardiovascular and metabolic diseases to this Special Issue.

Prof. Dr. Suowen Xu
Dr. Li Wang
Prof. Dr. Yu Huang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cardiovascular disease
  • metabolic disease
  • pharmacotherapy
  • biomarker
  • diagnostics

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2214 KiB  
Article
Coronary Artery Disease with Elevated Levels of HDL Cholesterol Is Associated with Distinct Lipid Signatures
by Wanying Xia, Haiyi Yu and Guisong Wang
Metabolites 2023, 13(6), 695; https://doi.org/10.3390/metabo13060695 - 26 May 2023
Viewed by 983
Abstract
Levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with the incidence of coronary artery disease (CAD). However, the underlying mechanism of CAD in the context of elevated HDL-C levels is unclear. Our study aimed to explore the lipid signatures in patients with [...] Read more.
Levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with the incidence of coronary artery disease (CAD). However, the underlying mechanism of CAD in the context of elevated HDL-C levels is unclear. Our study aimed to explore the lipid signatures in patients with CAD and elevated HDL-C levels and to identify potential diagnostic biomarkers for these conditions. We measured the plasma lipidomes of forty participants with elevated HDL-C levels (men with >50 mg/dL and women with >60 mg/dL), with or without CAD, using liquid chromatography–tandem mass spectrometry. We analyzed four hundred fifty-eight lipid species and identified an altered lipidomic profile in subjects with CAD and high HDL-C levels. In addition, we identified eighteen distinct lipid species, including eight sphingolipids and ten glycerophospholipids; all of these, except sphingosine-1-phosphate (d20:1), were higher in the CAD group. Pathways for sphingolipid and glycerophospholipid metabolism were the most significantly altered. Moreover, our data led to a diagnostic model with an area under the curve of 0.935, in which monosialo-dihexosyl ganglioside (GM3) (d18:1/22:0), GM3 (d18:0/22:0), and phosphatidylserine (38:4) were combined. We found that a characteristic lipidome signature is associated with CAD in individuals with elevated HDL-C levels. Additionally, the disorders of sphingolipid as well as glycerophospholipid metabolism may underlie CAD. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Cardiovascular and Metabolic Diseases)
►▼ Show Figures

Figure 1

12 pages, 742 KiB  
Article
Hospitalization Burden of Patients with Kidney Stones and Metabolic Comorbidities in Spain during the Period 2017–2020
by Javier Sáenz-Medina, Jesús San Román, María Rodríguez-Monsalve, Manuel Durán, Joaquín Carballido, Dolores Prieto and Ángel Gil Miguel
Metabolites 2023, 13(4), 574; https://doi.org/10.3390/metabo13040574 - 18 Apr 2023
Viewed by 1117
Abstract
Nephrolithiasis has become an increasing worldwide problem during the last decades. Metabolic syndrome, its components, and related dietary factors have been pointed out as responsible for the increasing incidence. The objective of this study was to evaluate the trends in the hospitalization rates [...] Read more.
Nephrolithiasis has become an increasing worldwide problem during the last decades. Metabolic syndrome, its components, and related dietary factors have been pointed out as responsible for the increasing incidence. The objective of this study was to evaluate the trends in the hospitalization rates of patients with nephrolithiasis, hospitalization features, costs, and how metabolic syndrome traits influence both the prevalence and complications of lithiasic patients. An observational retrospective study was conducted by analyzing hospitalization records from the minimum basic data set, including all patient hospitalizations in Spain in which nephrolithiasis has been coded as a main diagnosis or as a comorbidity during the period 2017–2020. A total of 106,407 patients were hospitalized and coded for kidney or ureteral lithiasis in this period. The mean age of the patients was 58.28 years (CI95%: 58.18–58.38); 56.8% were male, and the median length of stay was 5.23 days (CI95%: 5.06–5.39). In 56,884 (53.5%) patients, kidney or ureteral lithiasis were coded as the main diagnosis; the rest of the patients were coded mostly as direct complications of kidney or ureteral stones, such as “non-pecified renal colic”, “acute pyelonephritis”, or “tract urinary infection”. The hospitalization rate was 56.7 (CI95%: 56.3–57.01) patients per 100,000 inhabitants, showing neither a significant increasing nor decreasing trend, although it was influenced by the COVID-19 pandemic. The mortality rate was 1.6% (CI95%: 1.5–1.7), which was higher, if lithiasis was coded as a comorbidity (3.4% CI95%: 3.2–3.6). Metabolic syndrome diagnosis component codes increased the association with kidney lithiasis when age was higher, reaching the highest in the eighth decade of life. Age, diabetes, and hypertension or lithiasis coded as a comorbidity were the most common causes associated with the mortality of lithiasic patients. In Spain, the hospitalization rate of kidney lithiasis has remained stable during the period of study. The mortality rate in lithiasic patients is higher in elderly patients, being associated with urinary tract infections. Comorbidity conditions such as diabetes mellitus and hypertension are mortality predictors. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Cardiovascular and Metabolic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop